SeaStar Medical Holding Corporation announced that the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration has determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled the post-approval study requirements as outlined in t